{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T20:52:39Z","timestamp":1792356759877,"version":"4.4.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2008,6,1]],"date-time":"2008-06-01T00:00:00Z","timestamp":1212278400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2008,6]]},"DOI":"10.1007\/s11926-008-0036-3","type":"journal-article","created":{"date-parts":[[2008,10,23]],"date-time":"2008-10-23T19:02:25Z","timestamp":1224788545000},"page":"218-227","source":"Crossref","is-referenced-by-count":171,"title":["Colchicine: Its mechanism of action and efficacy in crystal-induced inflammation"],"prefix":"10.1007","volume":"10","author":[{"given":"George","family":"Nuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,10,24]]},"reference":[{"key":"36_CR1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.rdc.2006.03.003","volume":"32","author":"G. Nuki","year":"2006","unstructured":"Nuki G: Treatment of crystal arthropathy\u2014history and advances. Rheum Dis Clin N Am 2006, 32:333\u2013357.","journal-title":"Rheum Dis Clin N Am"},{"key":"36_CR2","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"K.L. Jordan","year":"2007","unstructured":"Jordan KL, Cameron S, Snaith M, et al.: British Society for Rheumatology and British Health Professionals in Rheumatology Guidelines for the Management of Gout. Rheumatology 2007, 46:1372\u20131374.","journal-title":"Rheumatology"},{"key":"36_CR3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00002281-199206000-00002","volume":"4","author":"S.B. Abramson","year":"1992","unstructured":"Abramson SB: Treatment of gout and crystal arthropathies and uses and mechanisms of action of nonsteroidal antiinflammatory drugs. Curr Opin Rheumatol 1992, 4:295\u2013300.","journal-title":"Curr Opin Rheumatol"},{"key":"36_CR4","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0049-0172(82)90065-8","volume":"12","author":"T. Yu","year":"1982","unstructured":"Yu T: The efficacy of colchicine prophylaxis in articular gout. A reappraisal after 20 years. Semin Arthritis Rheum 1982, 12:256\u2013264.","journal-title":"Semin Arthritis Rheum"},{"key":"36_CR5","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1056\/NEJM198706183162502","volume":"316","author":"R.W. Kunei","year":"1987","unstructured":"Kunei RW, Duncan GJ, Watson D, et al.: Colchicine myopathy and neuropathy. N Engl J Med 1987, 316:1562\u20131568.","journal-title":"N Engl J Med"},{"key":"36_CR6","first-page":"264","volume":"18","author":"S.L. Wallace","year":"1991","unstructured":"Wallace SL, Singer JZ, Duncan GJ, et al.: Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991, 18:264\u2013269.","journal-title":"J Rheumatol"},{"key":"36_CR7","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00000441-193610000-00006","volume":"192","author":"A. Cohen","year":"1936","unstructured":"Cohen A: Gout. Am J Med Sci 1936, 192:448\u2013493.","journal-title":"Am J Med Sci"},{"key":"36_CR8","first-page":"2429","volume":"31","author":"G.C. Borstad","year":"2004","unstructured":"Borstad GC, Bryant LR, Abel MP, et al.: Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. J Rheumatol 2004, 31:2429\u20132432.","journal-title":"J Rheumatol"},{"key":"36_CR9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.1780170517","volume":"17","author":"H.E. Paulus","year":"1974","unstructured":"Paulus HE, Schlosstein LH, Godfrey RG, et al.: Prophylactic colchicine therapy in intercritical gout. A placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1974, 17:609\u2013614.","journal-title":"Arthritis Rheum"},{"key":"36_CR10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0049-0172(74)90006-7","volume":"3","author":"S.L. Wallace","year":"1974","unstructured":"Wallace SL: Colchicine. Semin Arthritis Rheum 1974, 3:369\u2013381.","journal-title":"Semin Arthritis Rheum"},{"key":"36_CR11","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/rheumatology\/keh640","volume":"44","author":"N. Dalbeth","year":"2005","unstructured":"Dalbeth N, Haskard DO: Mechanisms of inflammation in gout. Rheumatology 2005, 44:1090\u20131096.","journal-title":"Rheumatology"},{"key":"36_CR12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/1529-0131(197605\/06)19:3+<439::AID-ART1780190719>3.0.CO;2-L","volume":"19","author":"N.S. Mandel","year":"1976","unstructured":"Mandel NS: The structural basis of membranolysis. Arthritis Rheum 1976, 19:439\u2013445.","journal-title":"Arthritis Rheum"},{"key":"36_CR13","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/art.1780250504","volume":"25","author":"B.C. Jaques","year":"1982","unstructured":"Jaques BC, Ginsberg MH: The role of cell surface proteins in platelet stimulation by monosodium urate crystals. Arthritis Rheum 1982, 25:508\u2013521.","journal-title":"Arthritis Rheum"},{"key":"36_CR14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1096\/fasebj.12.2.209","volume":"12","author":"F. Barabe","year":"1998","unstructured":"Barabe F, Gilbert C, Liao N, et al.: Crystal-induced neutrophil activation. VI. Involvement of FcgammaRIIIB (CD16) and CDIIb in response to inflammatory microcrystals. FASEB J 1998, 12:209\u2013220.","journal-title":"FASEB J"},{"key":"36_CR15","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1002\/art.21238","volume":"52","author":"R. Liu-Bryan","year":"2005","unstructured":"Liu-Bryan R, Scott P, Sydlaske A, et al.: Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005, 52:2936\u20132946.","journal-title":"Arthritis Rheum"},{"key":"36_CR16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nri1391","volume":"4","author":"S. Akira","year":"2004","unstructured":"Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499\u2013511.","journal-title":"Nat Rev Immunol"},{"key":"36_CR17","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nature01991","volume":"425","author":"Y. Shi","year":"2003","unstructured":"Shi Y, Evans JE, Rock KL: Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516\u2013521.","journal-title":"Nature"},{"key":"36_CR18","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1172\/JCI28075","volume":"116","author":"C.J. Chen","year":"2006","unstructured":"Chen CJ, Shi Y, Hearn A, et al.: MyD88-dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J Clin Invest 2006, 116:2262\u20132271.","journal-title":"J Clin Invest"},{"key":"36_CR19","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.4049\/jimmunol.138.10.3213","volume":"128","author":"F.S. Giovine di","year":"1987","unstructured":"di Giovine FS, Malawista SE, Nuki G, et al.: Interleukin-1 (IL-1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystalinduced IL-1. J Immunol 1987, 128:3213\u20133218.","journal-title":"J Immunol"},{"key":"36_CR20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0952-7915(02)00017-1","volume":"15","author":"K. Burns","year":"2003","unstructured":"Burns K, Martinon F, Tschopp J: New insights into the mechanism of IL-1beta maturation. Curr Opin Immunol 2003, 15:26\u201330.","journal-title":"Curr Opin Immunol"},{"key":"36_CR21","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","volume":"10","author":"F. Martinon","year":"2002","unstructured":"Martinon F, Burns K, Tschopp J: The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-1beta. Mol Cell 2002, 10:417\u2013426.","journal-title":"Mol Cell"},{"key":"36_CR22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F. Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, et al.: Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237\u2013241.","journal-title":"Nature"},{"key":"36_CR23","doi-asserted-by":"crossref","first-page":"6370","DOI":"10.4049\/jimmunol.177.9.6370","volume":"177","author":"P. Scott","year":"2006","unstructured":"Scott P, Ma H, Viriyakosol S, et al.: Engagement of CD14 mediates the inflammatory potential of monosodium urate crystals. J Immunol 2006, 177:6370\u20136378.","journal-title":"J Immunol"},{"key":"36_CR24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jbspin.2007.04.004","volume":"74","author":"V. Petrilli","year":"2007","unstructured":"Petrilli V, Martinon F: The inflammasome, autoinflammatory diseases and gout. Joint Bone Spine 2007, 74:571\u2013576.","journal-title":"Joint Bone Spine"},{"key":"36_CR25","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/sj.cdd.4402195","volume":"14","author":"V. Petrilli","year":"2007","unstructured":"Petrilli V, Papin S, Dostert C, et al.: Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration. Cell Death Differ 2007, 14:1583\u20131589.","journal-title":"Cell Death Differ"},{"key":"36_CR26","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.1780260612","volume":"26","author":"R. Terkeltaub","year":"1983","unstructured":"Terkeltaub R, Tenner AJ, Kozin F, et al.: Plasma protein binding by monosodium urate crystals: analysis by two dimensional gel electrophoresis. Arthritis Rheum 1983, 26:775\u2013783.","journal-title":"Arthritis Rheum"},{"key":"36_CR27","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1172\/JCI109360","volume":"63","author":"P.C. Giclas","year":"1979","unstructured":"Giclas PC, Ginsberg MH, Cooper NR: Immunoglobulin G independent activation of the classical complement pathway by monosodium urate crystals. J Clin Invest 1979, 63:759\u2013765.","journal-title":"J Clin Invest"},{"key":"36_CR28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.42.3.285","volume":"42","author":"M. Doherty","year":"1983","unstructured":"Doherty M, Whicher JT, Dieppe PA: Activation of the alternative pathway of complement by monosodium urate crystals and other inflammatory particles. Ann Rheum Dis 1983, 42:285\u2013291.","journal-title":"Ann Rheum Dis"},{"key":"36_CR29","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0090-1229(83)90143-5","volume":"26","author":"T.R. Fields","year":"1983","unstructured":"Fields TR, Abramson SB, Weissman G, et al.: Activation of the alternative pathway of complement by monosodium urate crystals. Clin Immunol Immunopathol 1983, 26:249\u2013257.","journal-title":"Clin Immunol Immunopathol"},{"key":"36_CR30","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/art.1780220603","volume":"22","author":"P. Hasselbacher","year":"1979","unstructured":"Hasselbacher P: C3 activation by monosodium urate and other crystalline material. Arthritis Rheum 1979, 22:571\u2013578.","journal-title":"Arthritis Rheum"},{"key":"36_CR31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0090-1229(82)90235-5","volume":"24","author":"I.J. Russell","year":"1963","unstructured":"Russell IJ, Mansen C, Kolb LM, et al.: Activation of the fifth component of human complement (C5) induced by monosodium urate crystals: C5 convertase assembly on the crystal surface. Clin Immunol Immunopathol 1963, 24:239\u2013250.","journal-title":"Clin Immunol Immunopathol"},{"key":"36_CR32","first-page":"425","volume":"10","author":"I.J. Russell","year":"1983","unstructured":"Russell IJ, Papaioannou C, McDuffie FC, et al.: Effects of IgG and C-reactive protein on complement depletion by monosodium urate crystals. J Rheumatol 1983, 10:425\u2013433.","journal-title":"J Rheumatol"},{"key":"36_CR33","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1182\/blood.V91.5.1769","volume":"91","author":"M. Pouliot","year":"1998","unstructured":"Pouliot M, James MJ, McColl SR, et al.: Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 1998, 91:1769\u20131776.","journal-title":"Blood"},{"key":"36_CR34","first-page":"602","volume":"10","author":"F.M. Wigley","year":"1983","unstructured":"Wigley FM, Fine IT, Newcombe DS: The role of the human synovial fibroblast in monosodium urate crystal-induced synovitis. J Rheumatol 1983, 10:602\u2013611.","journal-title":"J Rheumatol"},{"key":"36_CR35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0046-8177(73)80013-9","volume":"4","author":"C.A. Agudelo","year":"1973","unstructured":"Agudelo CA, Schumacher HR: The synovitis of acute gouty arthritis: a light and electron microscopic study. Human Pathol 1973, 4:265\u2013279.","journal-title":"Human Pathol"},{"key":"36_CR36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1084\/jem.124.1.115","volume":"124","author":"P. Phelps","year":"1966","unstructured":"Phelps P, McCarty DJ Jr: Crystal-induced inflammation in canine joints. II. Importance of polymorphonuclear leucocytes. J Exp Med 1966, 124:115\u2013126.","journal-title":"J Exp Med"},{"key":"36_CR37","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/art.1780400525","volume":"40","author":"P.T. Chapman","year":"1997","unstructured":"Chapman PT, Yarwood H, Harrison AA, et al.: Endothelial activation in monosodium urate monohydrate crystalinduced inflammation: in-vitro and in-vivo studies on the roles of tumor necrosis factor alpha and interleukin-1. Arthritis Rheum 1997, 40:955\u2013965.","journal-title":"Arthritis Rheum"},{"key":"36_CR38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/jcp.1041650106","volume":"165","author":"H. Meng","year":"1995","unstructured":"Meng H, Tonnesen MG, Marchese MJ, et al.: Mast cells are potent regulators of endothelial cell adhesion molecule ICAM-1 and VCAM-1 expression. J Cell Physiol 1995, 165:40\u201353.","journal-title":"J Cell Physiol"},{"key":"36_CR39","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1172\/JCI115142","volume":"87","author":"F.S. Giovine di","year":"1991","unstructured":"di Giovine FS, Malawista SE, Thornton E, Duff GW: Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. J Clin Invest 1991, 87:1375\u20131381.","journal-title":"J Clin Invest"},{"key":"36_CR40","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/anr.1780321114","volume":"32","author":"P.A. Guerne","year":"1989","unstructured":"Guerne PA, Terkeltaub R, Zuraw B, et al.: Inflammatory microcrystals stimulate interleukin-6 production and secretion by human monocytes and synoviocytes. Arthritis Rheum 1989, 32:1443\u20131552.","journal-title":"Arthritis Rheum"},{"key":"36_CR41","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/art.1780340716","volume":"34","author":"R. Terkeltaub","year":"1991","unstructured":"Terkeltaub R, Zachariae C, Santoro D, et al.: Monocyte-derived neutrophil chemotactic factor\/interleukin-8 is a potential mediator of crystal-induced inflammation. Arthritis Rheum 1991, 34:894\u2013903.","journal-title":"Arthritis Rheum"},{"key":"36_CR42","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/1529-0131(199805)41:5<900::AID-ART18>3.0.CO;2-K","volume":"41","author":"R. Terkeltaub","year":"1998","unstructured":"Terkeltaub R, Baird S, Sears P, et al.: The murine homolog of the interleukin-8 receptor CXCR-2 is essential for the occurrence of neutrophilic inflammation in the air pouch model of acute urate-induced gouty synovitis. Arthritis Rheum 1998, 41:900\u2013909.","journal-title":"Arthritis Rheum"},{"key":"36_CR43","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1002\/art.20386","volume":"50","author":"N. Tramontini","year":"2004","unstructured":"Tramontini N, Huber C, Liu-Bryan R, et al.: Central role of complement membrane attack complex in monosodium urate crystal-induced neutrophilic rabbit knee synovitis. Arthritis Rheum 2004, 50:2633\u20132639.","journal-title":"Arthritis Rheum"},{"key":"36_CR44","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1002\/art.11079","volume":"48","author":"C. Ryckman","year":"2003","unstructured":"Ryckman C, McColl SR, Vandal K, et al.: Role of S100A8 and S100A9 in neutrophil recruitment in response to monosodium urate monohydrate crystals in the air-pouch model of acute gouty arthritis. Arthritis Rheum 2003, 48:2310\u20132320.","journal-title":"Arthritis Rheum"},{"key":"36_CR45","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.4049\/jimmunol.152.11.5485","volume":"152","author":"C.J. Roberge","year":"1994","unstructured":"Roberge CJ, de Medicis R, Dayer JM, et al.: Crystal-induced neutrophil activation. V. Differential production of biologically active IL-1 and IL-1 receptor antagonist. J Immmunol 1994, 152:5485\u20135394.","journal-title":"J Immmunol"},{"key":"36_CR46","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1084\/jem.182.6.2019","volume":"182","author":"M. Hachicha","year":"1995","unstructured":"Hachicha M, Nacchache PH, McColl SR: Inflammatory microcrystals differentially regulate secretion of macrophage inflammatory protein 1 and interleukin 8 by human neutrophils: a possible mechanism of neutrophil recruitment to sites of inflammation in synovitis. J Exp Med 1995, 182:2019\u20132025.","journal-title":"J Exp Med"},{"key":"36_CR47","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/art.10851","volume":"48","author":"C. Gilbert","year":"2003","unstructured":"Gilbert C, Poubelle PE, Borgeat P, et al.: Crystal-induced neutrophil activation: VIII. Immediate production of prostaglandin E2 mediated by constitutive cyclooxygenase 2 in human neutrophils stimulated by urate crystals. Arthritis Rheum 2003, 48:1137\u20131148.","journal-title":"Arthritis Rheum"},{"key":"36_CR48","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/art.1780250210","volume":"25","author":"S. Abramson","year":"1982","unstructured":"Abramson S, Hoffstein ST, Weissman G: Superoxide anion generation by human neutrophils exposed to monosodium urate. Arthritis Rheum 1982, 25:174\u2013180.","journal-title":"Arthritis Rheum"},{"key":"36_CR49","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/art.1780250211","volume":"25","author":"L. Simchowitz","year":"1982","unstructured":"Simchowitz L, Atkinson JP, Spilberg I: Stimulation of the respiratory burst in human neutrophils by crystal phagocytosis. Arthritis Rheum 1982, 25:181\u2013188.","journal-title":"Arthritis Rheum"},{"key":"36_CR50","first-page":"2357","volume-title":"Arthritis and Allied Conditions","author":"R. Terkeltaub","year":"2004","unstructured":"Terkeltaub R: Pathogenesis and treatment of crystal-induced inflammation. In Arthritis and Allied Conditions, 15th edn. Edited by Koopman WJ, Moreland LW. Philadelphia: Lippincott, Williams and Wilkins; 2004:2357\u20132372.","edition":"15"},{"key":"36_CR51","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1172\/JCI111380","volume":"73","author":"R. Terkeltaub","year":"1984","unstructured":"Terkeltaub R, Curtiss LK, Tenner AJ, et al.: Lipoproteins containing apoprotein B are a major regulator of neutrophil responses to monosodium urate crystals. J Clin Invest 1984, 73:1719\u20131730.","journal-title":"J Clin Invest"},{"key":"36_CR52","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1172\/JCI114971","volume":"87","author":"R. Terkeltaub","year":"1991","unstructured":"Terkeltaub R, Dyer CA, Martin J, et al.: Apolipoprotein (apo) E inhibits the capacity of monosodium urate crystals to stimulate neutrophils. Characterization of intraarticular apo E and demonstration of apo E binding to urate crystals in-vivo. J Clin Invest 1991, 87:20\u201326.","journal-title":"J Clin Invest"},{"key":"36_CR53","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/art.10526","volume":"46","author":"S.J. Getting","year":"2002","unstructured":"Getting SJ, Christian HC, Flower RJ, et al.: Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002, 46:2765\u20132775.","journal-title":"Arthritis Rheum"},{"key":"36_CR54","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/art.10709","volume":"48","author":"T. Akahoshi","year":"2003","unstructured":"Akahoshi T, Namai R, Murakami Y, et al.: Rapid induction of peroxisome proliferator-activated receptor gamma expression in human monocytes by monosodium urate monohydrate crystals. Arthritis Rheum 2003, 48:231\u2013239.","journal-title":"Arthritis Rheum"},{"key":"36_CR55","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1172\/JCI1112","volume":"101","author":"V.A. Fadok","year":"1998","unstructured":"Fadok VA, Bratton DL, Konowal A, et al.: Macrophages that have ingested apoptotic cells in-vitro inhibit proinflammatory cytokine production through autocrine\/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998, 101:890\u2013898.","journal-title":"J Clin Invest"},{"key":"36_CR56","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1002\/art.22137","volume":"54","author":"D.M. Rose","year":"2006","unstructured":"Rose DM, Sydlaske AD, Agha-Babakhani A, et al.: Transglutaminase 2 limits murine peritoneal acute gout-like inflammation by regulating macrophage clearance of apoptotic neutrophils. Arthritis Rheum 2006, 54:3363\u20133371.","journal-title":"Arthritis Rheum"},{"key":"36_CR57","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/art.20317","volume":"50","author":"D.R. Yagnik","year":"2004","unstructured":"Yagnik DR, Evans BJ, Florey O, et al.: Macrophage release of transforming growth factor beta 1 during resolution of monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2004, 50:2273\u20132280.","journal-title":"Arthritis Rheum"},{"key":"36_CR58","doi-asserted-by":"crossref","first-page":"13560","DOI":"10.1021\/bi00212a023","volume":"32","author":"D.L. Sackett","year":"1993","unstructured":"Sackett DL, Varma JK: Molecular mechanism of colchicine action; induced local unfolding of beta-tubulin. Biochemistry 1993, 32:13560\u201313565.","journal-title":"Biochemistry"},{"key":"36_CR59","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.tcb.2006.08.002","volume":"16","author":"J.P. Caviston","year":"2006","unstructured":"Caviston JP, Holzbauer EL: Microtubule motors at the intersection of trafficking and transport. Trends Cell Biol 2006, 16:530\u2013537.","journal-title":"Trends Cell Biol"},{"key":"36_CR60","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/art.1780080438","volume":"8","author":"J.E. Caner","year":"1965","unstructured":"Caner JE: Colchicine inhibition of chemotaxis. Arthritis Rheum 1965, 8:752\u2013757.","journal-title":"Arthritis Rheum"},{"key":"36_CR61","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/art.1780160608","volume":"16","author":"D.G. Wright","year":"1973","unstructured":"Wright DG, Malawista SE: Mobilization and extracellular release of granular enzymes from human leucocytes during phagocytosis: inhibition by cortisol and colchicine but not by salicylates. Arthritis Rheum 1973, 16:749\u2013758.","journal-title":"Arthritis Rheum"},{"key":"36_CR62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.1780130101","volume":"13","author":"P. Phelps","year":"1970","unstructured":"Phelps P: Polymorphonuclear leukocyte mobility in-vitro. IV. Colchicine inhibition of chemotactic activity formation after phagocytosis of urate crystals. Arthritis Rheum 1970, 13:1\u20139.","journal-title":"Arthritis Rheum"},{"key":"36_CR63","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1172\/JCI109523","volume":"64","author":"I. Spilberg","year":"1979","unstructured":"Spilberg I, Mandell B, Mehta J, et al.: Mechanism of action of colchicine in acute urate crystal-induced arthritis. J Clin Invest 1979, 64:775\u2013780.","journal-title":"J Clin Invest"},{"key":"36_CR64","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1002\/art.23069","volume":"58","author":"D.J. McCarty","year":"2008","unstructured":"McCarty DJ: Urate crystals, inflammation and colchicine. Arthritis Rheum 2008, 58:S20\u2013S24.","journal-title":"Arthritis Rheum"},{"issue":"Suppl1","key":"36_CR65","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1186\/ar1908","volume":"8","author":"B.N. Cronstein","year":"2006","unstructured":"Cronstein BN, Terkeltaub R: The inflammatory process of gout and its treatment. Arthritis Res Ther 2006, 8(Suppl 1):S3.","journal-title":"Arthritis Res Ther"},{"key":"36_CR66","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1172\/JCI116759","volume":"92","author":"C.J. Roberge","year":"1993","unstructured":"Roberge CJ, Gaudry M, de Medicis R, et al.: Crystal-induced neutrophil activation. IV. Specific inhibition of tyrosine phosphorylation by colchicine. J Clin Invest 1993, 92:1722\u20131729.","journal-title":"J Clin Invest"},{"key":"36_CR67","first-page":"559","volume":"78","author":"A. Mutsukawa","year":"1998","unstructured":"Mutsukawa A, Yoshimura T, Maeda T, et al.: Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-1 beta, interleukin-8, and interleukin-1 beta receptor antagonist in monosodium urate crystal-induced rabbit arthritis. Lab Invest 1998, 78:559\u2013569.","journal-title":"Lab Invest"},{"key":"36_CR68","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s00296-004-0442-4","volume":"25","author":"E. Ben Chetrit","year":"2005","unstructured":"Ben Chetrit E, Fischel R, Hinz B, et al.: The effects of colchicine and hydroxychloroquine on the cyclooxygenases COX-1 and COX-2. Rheumatol Int 2005, 25:332\u2013335.","journal-title":"Rheumatol Int"},{"key":"36_CR69","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/art.22938","volume":"56","author":"R.M. Pope","year":"2007","unstructured":"Pope RM, Tschopp J: The role of interleukin-1 and the inflammasome in gout. Arthritis Rheum 2007, 56:3183\u20133188.","journal-title":"Arthritis Rheum"},{"key":"36_CR70","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1172\/JCI118147","volume":"96","author":"B.N. Cronstein","year":"1995","unstructured":"Cronstein BN, Molad Y, Reibman J, et al.: Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995, 96:994\u20131002.","journal-title":"J Clin Invest"},{"key":"36_CR71","first-page":"498","volume":"13","author":"J.O. Minta","year":"1986","unstructured":"Minta JO, Williams MD: Interactions of antirheumatic drugs with the superoxide generation system of activated human polymorphonuclear leukocytes. J Rheumatol 1986, 13:498\u2013504.","journal-title":"J Rheumatol"},{"key":"36_CR72","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1038\/bjp.2008.20","volume":"153","author":"E.W. Chia","year":"2008","unstructured":"Chia EW, Grainger R, Harper JL: Colchicine suppresses neutrophil superoxide production in a murine model of gouty arthritis: a rationale for use of low-dose colchicine. Br J Pharmacol 2008, 153:1288\u20131295.","journal-title":"Br J Pharmacol"},{"key":"36_CR73","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jbspin.2006.03.006","volume":"73","author":"E. Niel","year":"2006","unstructured":"Niel E, Scherrmann JM: Colchicine today. Joint Bone Spine 2006, 73:672\u2013678.","journal-title":"Joint Bone Spine"},{"key":"36_CR74","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/clpt.1993.161","volume":"54","author":"O.N. Chappey","year":"1993","unstructured":"Chappey ON, Niel E, Wautier JL, et al.: Colchicine disposition in human leucocytes after single and multiple oral administration. Clin Pharmacol Ther 1993, 54:360\u2013367.","journal-title":"Clin Pharmacol Ther"},{"key":"36_CR75","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0022-3565(25)38448-X","volume":"268","author":"I.A. Lannoy de","year":"1994","unstructured":"de Lannoy IA, Mandin RS, Silverman M: Renal secretion of vinblastine, vincristine and colchicine in-vivo. J Pharmacol Exp Med 1994, 268:388\u2013395.","journal-title":"J Pharmacol Exp Med"},{"key":"36_CR76","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/BF01393768","volume":"27","author":"M. Ehrenfeld","year":"1982","unstructured":"Ehrenfeld M, Levy M, Sharon P, et al.: Gastrointestinal effects of long-term colchicine therapy in patients with recurrent polyserositis. Dig Dis Sci 1982, 27:723\u2013727.","journal-title":"Dig Dis Sci"},{"key":"36_CR77","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3109\/00365529409094847","volume":"29","author":"J. Rudi","year":"1994","unstructured":"Rudi J, Raedsch R, Gerteis C, et al.: Plasma kinetics and biliary excretion of colchicine in patients with chronic liver disease after oral administration of a single dose and after long-term treatment. Scand J Gastroenterol 1994, 29:346\u2013351.","journal-title":"Scand J Gastroenterol"},{"key":"36_CR78","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0022-3565(25)10989-0","volume":"261","author":"K.V. Speeg","year":"1992","unstructured":"Speeg KV, Maldonado AL, Liaci J, et al.: Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studied in-vivo. J Phamacol Exp Med 1992, 261:50\u201355.","journal-title":"J Phamacol Exp Med"},{"key":"36_CR79","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/hep.1840150524","volume":"15","author":"K.V. Speeg","year":"1992","unstructured":"Speeg KV, Maldonado AL, Liaci J, et al.: Effect of cyclosporine on colchicine secretion by a liver canalicular transporter studied in-vivo. Hepatology 1992, 15:899\u2013903.","journal-title":"Hepatology"},{"key":"36_CR80","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1136\/bmj.38568.639688.F7","volume":"331","author":"U. Troger","year":"2005","unstructured":"Troger U, Lins H, Scherrmann JM, et al.: Tetraparesis associated with colchicine is probably due to inhibition by verapamil of the P-glycoprotein efflux pump in the blood brain barrier. BMJ 2005, 331:613.","journal-title":"BMJ"},{"key":"36_CR81","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W. Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, et al.: EULAR evidence-based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006, 65:1312\u20131324.","journal-title":"Ann Rheum Dis"},{"key":"36_CR82","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1445-5994.1987.tb01232.x","volume":"17","author":"M.J. Ahern","year":"1987","unstructured":"Ahern MJ, Reid C, Gordon TP, et al.: Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987, 17:301\u2013304.","journal-title":"Aust N Z J Med"},{"key":"36_CR83","first-page":"U2402","volume":"120","author":"V. Jayaprakash","year":"2007","unstructured":"Jayaprakash V, Ansell G, Galler D: Colchicine overdosage: the devil is in the detail. NZ Med J 2007, 120:U2402.","journal-title":"NZ Med J"},{"key":"36_CR84","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1111\/j.1742-1241.2007.01556.x","volume":"61","author":"R. Grahame","year":"2007","unstructured":"Grahame R: Is there still a place for colchicine in the treatment of acute gout? Int J Clin Pract 2007, 61:1966\u20131967.","journal-title":"Int J Clin Pract"},{"key":"36_CR85","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1136\/bmj.327.7426.1275","volume":"327","author":"I. Morris","year":"2003","unstructured":"Morris I, Varughese G, Mattingly P: Colchicine in acute gout. BMJ 2003, 327:1275\u20131276.","journal-title":"BMJ"},{"key":"36_CR86","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1592\/phco.24.17.1784.52334","volume":"24","author":"F. Wilbur","year":"2004","unstructured":"Wilbur F, Makowski M: Colchicine myotoxicity: case reports and literature review. Pharmacotherapy 2004, 24:1784\u20131792.","journal-title":"Pharmacotherapy"},{"key":"36_CR87","first-page":"2045","volume":"24","author":"T.M. Dawson","year":"1997","unstructured":"Dawson TM, Starkebaum G: Colchicine induced rhabdomyolysis. J Rheumatol 1997, 24:2045\u20132046.","journal-title":"J Rheumatol"},{"key":"36_CR88","doi-asserted-by":"crossref","unstructured":"Schlesinger N, Schumacher R, Catton M, et al.: Colchicine for acute gout. Cochrane Database Syst Rev 2006, (4):CD006190.","DOI":"10.1002\/14651858.CD006190"},{"key":"36_CR89","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/archinte.1977.03630150088024","volume":"137","author":"R.M. Naidus","year":"1997","unstructured":"Naidus RM, Rodvein R, Mielke CH Jr: Colchicine toxicity: a multisystem disease. Arch Intern Med 1997, 137:394\u2013396.","journal-title":"Arch Intern Med"},{"key":"36_CR90","first-page":"710","volume":"21","author":"E. Ben Chetrit","year":"1994","unstructured":"Ben Chetrit E, Scherrmann JM, Zylber-Katz E, et al.: Colchicine disposition in patients with familial Mediterranean fever with renal impairment. J Rheumatol 1994, 21:710\u2013713.","journal-title":"J Rheumatol"},{"key":"36_CR91","first-page":"421","volume":"16","author":"E.E. Minetti","year":"2003","unstructured":"Minetti EE, Minetti L: Multiple organ failure in a kidney transplant patient receiving both colchicine and cyclosporine. J Nephrol 2003, 16:421\u2013425.","journal-title":"J Nephrol"},{"key":"36_CR92","first-page":"494","volume":"19","author":"Y. Caraco","year":"1992","unstructured":"Caraco Y, Putterman C, Rahamimov R, et al.: Acute colchicine intoxication\u2014a possible role of erythromycin administration. J Rheumatol 1992, 19:494\u2013496.","journal-title":"J Rheumatol"},{"key":"36_CR93","unstructured":"Medsafe Pharmacovigilance Team: Colchicine: lower doses for greater safety. Available at http:\/\/www.medsafe.govt.nz\/profs\/puarticles\/colchdose.htm . Accessed April 23, 2008."},{"key":"36_CR94","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1056\/NEJM199602153340707","volume":"334","author":"B.T. Emmerson","year":"1996","unstructured":"Emmerson BT: The management of gout. N Engl J Med 1996, 334:445\u2013451.","journal-title":"N Engl J Med"},{"key":"36_CR95","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0736-4679(02)00430-4","volume":"22","author":"R.A. Bonnel","year":"2002","unstructured":"Bonnel RA, Villalba ML, Karwoski CB, Beitz J: Deaths associated with inappropriate intravenous colchicine administration. J Emerg Med 2002; 22:385\u2013387.","journal-title":"J Emerg Med"},{"key":"36_CR96","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1517\/14740338.6.6.625","volume":"6","author":"N. Schlesinger","year":"2007","unstructured":"Schlesinger N: Reassessing the safety of intravenous and compounded injectable colchicine in acute gout treatment. Expert Opin Drug Safety 2007, 6:625\u2013629.","journal-title":"Expert Opin Drug Safety"},{"key":"36_CR97","unstructured":"US Food and Drug Administration: Questions and answers about FDA\u2019s enforcement action against unapproved injectable colchicine products. Available at http:\/\/www.fda.gov\/cder\/drug\/unapproved_drugs\/colchicine_qa.htm . Accessed April 1, 2008."},{"key":"36_CR98","first-page":"1050","volume":"56","author":"Centers for Disease ControlPrevention","year":"2007","unstructured":"Centers for Disease Control and Prevention: Deaths from intravenous colchicine resulting from a compounding pharmacy error\u2014Oregon and Washington 2007. MMWR Morb Mortal Wkly Rep 2007, 56:1050\u20131052.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"36_CR99","first-page":"495","volume":"15","author":"S.L. Wallace","year":"1988","unstructured":"Wallace SL, Singer JZ: Systemic toxicity associated with the intravenous administration of colchicine\u2014guidelines for use. J Rheumatol 1988, 15:495\u2013499.","journal-title":"J Rheumatol"},{"key":"36_CR100","first-page":"804","volume":"13","author":"A. Alvarellos","year":"1986","unstructured":"Alvarellos A, Spilberg I: Colchicine prophylaxis in pseudogout. J Rheumatol 1986, 13:804\u2013805.","journal-title":"J Rheumatol"},{"key":"36_CR101","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0889-857X(21)00376-8","volume":"21","author":"A.K. Rosenthal","year":"1995","unstructured":"Rosenthal AK, Ryan LM: Treatment of refractory crystalassociated arthritis. Rheum Dis Clin North Am 1995, 21:151\u2013161.","journal-title":"Rheum Dis Clin North Am"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-008-0036-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-008-0036-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-008-0036-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T05:55:00Z","timestamp":1738475700000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-008-0036-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,6]]},"references-count":101,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,6]]}},"alternative-id":["36"],"URL":"https:\/\/doi.org\/10.1007\/s11926-008-0036-3","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,6]]}}}